- Sona Nanotech (SONA) received the second set of results from the U.S. National Cancer Institute’s Nanotechnology Characterization Laboratory
- The lab conducted an independent assessment of Sona’s proprietary gold nanorod nanoparticles
- The assessment included analyses of two additional batches of Sona’s gold nanorods for consistency of physiochemical characterization and microbial contamination and endotoxin levels
- Sona Nanotech (SONA) opened trading at $0.17 per share
Sona Nanotech (SONA) received the second set of results from the U.S. National Cancer Institute’s Nanotechnology Characterization Laboratory.
The lab conducted an independent assessment of Sona’s proprietary gold nanorod nanoparticles.
The assessment included analyses of two additional batches of Sona’s gold nanorods for consistency of physiochemical characterization and microbial contamination and endotoxin levels.
David Regan, CEO of Sona, commented on the news.
“Getting the approval of regulators to run clinical trials for targeted hyperthermia therapy will require a mountain of compelling data. These lab assessments of the biocompatibility of our core, gold nanorod technology, coupled with the existing small animal study data for the therapy will provide us with a great base on which to build in the coming months.”
The lab will continue to work with Sona to conduct further studies that could support any submission for the use of Sona’s gold nanorods in Sona’s targeted hyperthermia therapy to the U.S. Food and Drug Administration, including a quantitation of the surfactant detected in the samples.
Sona Nanotech is a nanotechnology life sciences firm that has developed multiple proprietary methods for the manufacture of various types of gold nanoparticles. The company researches and develops gold nanorod products. It makes products for diagnostic tests and medical treatment applications. The company’s product includes Gemini and saliva tests.
Sona Nanotech (SONA) opened trading at $0.17 per share.